Unmet Care Needs and Financial Hardship in Patients With Metastatic Non-Small-Cell Lung Cancer on Immunotherapy or Chemoimmunotherapy in Clinical Practice.

Purpose: Immunotherapy or chemoimmunotherapy is now standard treatment for most patients with metastatic non-small-cell lung cancer (mNSCLC), yet patient supportive care needs (SCNs) on immunotherapy are not well defined. This study characterized the SCNs and financial hardship of patients with mNSCLC treated with immunotherapy or chemoimmunotherapy and examined the relationship between patient and caregiver cancer-related employment reductions and patient financial hardship.
Methods: Patients with mNSCLC on immunotherapy or chemoimmunotherapy from a single academic medical center completed the SCNs Survey-34, items indexing material, psychological, and behavioral financial hardship, and the Comprehensive Score for Financial Toxicity. Univariate and bivariate analyses examined care needs, financial hardship, and impact of cancer-related employment reductions on patient financial hardship.
Results: Sixty patients (40% male; 75% White, mean age = 62.5 years, 57% on immunotherapy alone) participated. Fifty-five percent reported unmet needs in physical or daily living and psychological domains. Financial hardship was common (33% material, 63% psychological, and 57% behavioral). Fifty-two percent reported hardship in at least two domains. Forty percent reported a caregiver cancer-related employment reduction. Caregiver employment reduction was related to patient financial hardship (68% of those reporting caregiver employment reduction reported at least two domains of hardship v 40% of those without reduction, P = .03) and patient financial distress (mean Comprehensive Score for Financial Toxicity = 19.6 among those with caregiver employment reduction v 26.8 without, P = .01).
Conclusion: Patients with mNSCLC treated with immunotherapy or chemoimmunotherapy report multiple unmet care needs and financial hardship. Psychological, functional, financial, and caregiver concerns merit assessment and intervention in this population.
Competing Interests: Thomas W. LycanTravel, Accommodations, Expenses: Incyte Jimmy RuizConsulting or Advisory Role: AstraZenecaSpeakers' Bureau: AstraZeneca, GenentechResearch Funding: AstraZeneca, Roche, BeyondSpring Pharmaceuticals, ER SquibTravel, Accommodations, Expenses: AstraZeneca, Genentech/Roche Stefan C. GrantEmployment: TheraBionicLeadership: TheraBionicStock and Other Ownership Interests: TheraBionicResearch Funding: Genentech Mypath, Loxo, Bristol-Myers Squibb, Rafael Pharmaceuticals, Guardant HealthTravel, Accommodations, Expenses: Florence Healthcare W. Jeffrey PettyConsulting or Advisory Role: Jazz PharmaceuticalsResearch Funding: Merck Sharp & Dohme, AbbvieTravel, Accommodations, Expenses: Dava OncologyNo other potential conflicts of interest were reported.